Matches in SemOpenAlex for { <https://semopenalex.org/work/W2611408758> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W2611408758 endingPage "229" @default.
- W2611408758 startingPage "225" @default.
- W2611408758 abstract "Diabetes Mellitus type 2 is very common worldwide, with majority of cases in Asia Pacific region. Metformin is the first line therapy, along with lifestyle modification for all type 2 diabetics as recommended by ADA. Metformin is available as conventional Metformin Immediate Release (MIR) and Metformin Extended Release (MXR). Metformin XR has better gastrointestinal tolerability and fewer side effects as compared to Metformin IR, with similar efficacy regarding anti-hyperglycaemic effects. The objective of this study was to determine whether metformin XR is as effective as Metformin IR in maintaining glycaemic control at equivalent doses or even at reduced doses; and to compare the side effect profile of the two preparations.This randomized control trial was conducted at Medical and Endocrinology OPD of Jinnah Hospital Lahore. A total of 90 type 2 diabetics of both genders were recruited using nonprobability purposive sampling. Patients were randomized into 3 groups; 30 in each group. Group 1 received Metformin IR 1000 mg twice daily; group 2 received metformin XR 1000 mg twice daily; and group 3 received metformin XR 500 mg twice daily, for a period of three months. HbA1c was done at baseline and after three months of therapy along with fasting blood sugars and random blood sugars weekly.The mean age of patients was 46±9 years, with 54% being males and 46% being females. There was a 1% reduction in HbA1c in group 1, 0.7% reduction in group 2 and only 0.4% reduction in group 3. Similarly, all three therapies were equally effective in reducing blood sugar fasting and blood sugar random at three months. Side effects namely diarrhoea, dyspepsia and flatulence were greatest with Metformin IR (40%) but less than half with Metformin XR at equivalent dose and negligible at half the dose.All three Metformin groups were effective in reduction of HbA1C and glycaemic control clinically and there is no statistical difference in HbA1c reduction among groups at three months." @default.
- W2611408758 created "2017-05-12" @default.
- W2611408758 creator A5004610938 @default.
- W2611408758 creator A5054730527 @default.
- W2611408758 creator A5075257053 @default.
- W2611408758 creator A5089682497 @default.
- W2611408758 date "2017-07-19" @default.
- W2611408758 modified "2023-09-28" @default.
- W2611408758 title "Dose Comparison And Side Effect Profile Of Metformin Extended Release Versus Metformin Immediate Release." @default.
- W2611408758 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28718236" @default.
- W2611408758 hasPublicationYear "2017" @default.
- W2611408758 type Work @default.
- W2611408758 sameAs 2611408758 @default.
- W2611408758 citedByCount "5" @default.
- W2611408758 countsByYear W26114087582021 @default.
- W2611408758 countsByYear W26114087582022 @default.
- W2611408758 countsByYear W26114087582023 @default.
- W2611408758 crossrefType "journal-article" @default.
- W2611408758 hasAuthorship W2611408758A5004610938 @default.
- W2611408758 hasAuthorship W2611408758A5054730527 @default.
- W2611408758 hasAuthorship W2611408758A5075257053 @default.
- W2611408758 hasAuthorship W2611408758A5089682497 @default.
- W2611408758 hasConcept C126322002 @default.
- W2611408758 hasConcept C134018914 @default.
- W2611408758 hasConcept C168563851 @default.
- W2611408758 hasConcept C197934379 @default.
- W2611408758 hasConcept C2777180221 @default.
- W2611408758 hasConcept C2778375690 @default.
- W2611408758 hasConcept C2780323712 @default.
- W2611408758 hasConcept C2910068830 @default.
- W2611408758 hasConcept C555293320 @default.
- W2611408758 hasConcept C71924100 @default.
- W2611408758 hasConcept C90924648 @default.
- W2611408758 hasConceptScore W2611408758C126322002 @default.
- W2611408758 hasConceptScore W2611408758C134018914 @default.
- W2611408758 hasConceptScore W2611408758C168563851 @default.
- W2611408758 hasConceptScore W2611408758C197934379 @default.
- W2611408758 hasConceptScore W2611408758C2777180221 @default.
- W2611408758 hasConceptScore W2611408758C2778375690 @default.
- W2611408758 hasConceptScore W2611408758C2780323712 @default.
- W2611408758 hasConceptScore W2611408758C2910068830 @default.
- W2611408758 hasConceptScore W2611408758C555293320 @default.
- W2611408758 hasConceptScore W2611408758C71924100 @default.
- W2611408758 hasConceptScore W2611408758C90924648 @default.
- W2611408758 hasIssue "2" @default.
- W2611408758 hasLocation W26114087581 @default.
- W2611408758 hasOpenAccess W2611408758 @default.
- W2611408758 hasPrimaryLocation W26114087581 @default.
- W2611408758 hasRelatedWork W1532760157 @default.
- W2611408758 hasRelatedWork W2003398326 @default.
- W2611408758 hasRelatedWork W2025436379 @default.
- W2611408758 hasRelatedWork W2032746366 @default.
- W2611408758 hasRelatedWork W2166498497 @default.
- W2611408758 hasRelatedWork W2401881665 @default.
- W2611408758 hasRelatedWork W3114127255 @default.
- W2611408758 hasRelatedWork W3130171081 @default.
- W2611408758 hasRelatedWork W3135879765 @default.
- W2611408758 hasRelatedWork W1920632900 @default.
- W2611408758 hasVolume "29" @default.
- W2611408758 isParatext "false" @default.
- W2611408758 isRetracted "false" @default.
- W2611408758 magId "2611408758" @default.
- W2611408758 workType "article" @default.